Compare Enveric Biosciences Inc (ENVB) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Wendys Co — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Wendys Co trades at $6.22 (market cap $1.19B). The key difference: Wendys Co is far larger — about 175× Enveric Biosciences Inc's market cap, and Wendys Co pays a 4.49% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Wendys Co for 77 Days on average.
| ENVB | WEN | |
|---|---|---|
Market Cap | $6.80M | $1.19B |
Volume | 64,867 | 5,622,905 |
Sector | Health | Consumer Cyclical |
52-Week High | $10.80 | $9.33 |
52-Week Low | $1.27 | $6.10 |
Typical Hold Time | 14 Days | 77 Days |
Enterprise Value | -$1.49M | $4.92B |
Dividend Yield | — | 4.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
Wendy's stock (WEN) trades at $6.11, down 0.81% recently, with a bearish technical signal and oversold RSI indicators. The company shows mixed fundamentals: it has beaten earnings estimates for three consecutive quarters but faces declining net income margins and high debt levels. Recent news highlights challenges, including a major franchisee bankruptcy and same-store sales declines, contributing to negative sentiment.
The outlook for WEN is cautious. While its low P/E ratio of 9.25 and consistent earnings beats offer value, risks from franchisee instability, competitive pressures, and declining profitability weigh on growth. Analyst consensus is a 'Hold' with a $7.58 price target, suggesting limited upside amid operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
